Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Javelin sues after contamination issues prompt Hospira to delay takeover

This article was originally published in Scrip

Executive Summary

Javelin Pharmaceuticals has filed suit in an attempt to force Hospira to complete its planned $145 million takeover and hand over a promised $2 million loan. The firm went to court after Hospira extended its tender offer for the second time, citing manufacturing issues which prompted a recall of Javelin's Dyloject (diclofenac injection) by Therabel, Javelin's commercial licensing partner in the UK.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts